Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03046836 · ClinicalTrials.gov registry record · Phase 2

Oxytocin, Alcohol Craving, and Intimate Partner Aggression

A Phase 2 study of Alcohol Use, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 2
Development phase
200
Enrollment target
1
Study location

NCT03046836 is a Phase 2 study of Alcohol Use that has completed, run by Medical University of South Carolina. The registered enrollment target is 200 participants, below the 262-participant average among 23 other Alcohol Use trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03046836, a Phase 2 study of Alcohol Use, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 2
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

Alcohol use disorders (AUD) and intimate partner aggression (IPA) frequently co-occur. There are significant health and economic burdens associated with AUD and co-occurring IPA, and little empirical data to guide treatment efforts. The neuropeptide oxytocin may help mitigate both AUD and IPA. However, clinical data examining oxytocin's effects on human aggression is scant. The proposed study is designed to address these gaps in the literature by utilizing a human laboratory paradigm to test the effects of oxytocin on craving and aggression among couples with AUD and co-occurring IPA.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Oxytocin

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2017-07-01
Est. Completion 2021-04-11
Phase Phase 2

What the Registry Record Tells You About NCT03046836

The ClinicalTrials.gov registry entry for NCT03046836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 262-participant average among 23 other Alcohol Use trials with a reported enrollment target (24% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcohol Use appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03046836 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT03046836 about?

NCT03046836 is a clinical study titled "Oxytocin, Alcohol Craving, and Intimate Partner Aggression". Alcohol use disorders (AUD) and intimate partner aggression (IPA) frequently co-occur. There are significant health and economic burdens associated with AUD and co-occurring IPA, and little empirical data to guide treatment efforts. The neuropeptide oxytocin may help mitigate both AUD and IPA. Howev...

What is the current status of trial NCT03046836?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2017-07-01. Estimated completion is 2021-04-11.

What conditions does trial NCT03046836 study?

This clinical trial studies the following conditions: Alcohol Use.

What interventions are being tested in trial NCT03046836?

The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).

Who is sponsoring clinical trial NCT03046836?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03046836 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.